CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

By B. E. C. Oiffier, E. R. L. Epage, J. Rière, R. A. H. Erbrecht, T. Illy, R. E. B. Ouabdallah, P. Ierre, M. Orel, E. R. V. A. D. E. N. Este, G. I. S. Alles and 3 more. 2002

4,162 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/c2bf88be4e6bfa3650067fd1cd70a4fd5ba29d06

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Ng
2. T. Hansel
3. L. Falzone
4. H. Kropshofer
5. T. Singer
6. S. Salomone
7. B. Leader
8. J. Mitchell

Citations in the corpus

• Chemotherapy and the war on cancer (2005, background): “Fortunately, clinical trials have demonstrated potent synergy between targeted molecules, particularly monoclonal antibodies such as rituximab (Rituxan”
• Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, result): “Similar benefits are also well documented with rituximab, in which inclusion of rituximab in a standard chemotherapy regimen resulted in an overall response rate of 76% compared with 63% with chemotherapy alone in patients with diffuse large B cell lymphom”
• Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “Furthermore, in 2002, a combination therapy including Rituximab and CHOP standard chemotherapy (Cyclophosphamide, Hydroxydaunorubicin (also called doxorubicin), Oncovin (vincristine), and Prednisone or Prednisolone) was proposed (Coiffier et al., 2002; Mounier et al., 2003).”
• Protein therapeutics: a summary and pharmacological classification (2008, background): “For example, rituximab is a human/mouse chimeric monoclonal antibody that binds to CD20, a transmembrane protein expressed on >90% of B-cell non-Hodgkin's lymphomas, and targets the cells for destruction by the body's immune syste”